The impact of canagliflozin on the risk of neuropathy events: results from the CREDENCE trial

Jinlan Liao 1,2
Amy Kang 1,3
Chao Xia 1,4
Gian Luca Di Tanna 1
Clare Arnott 1,5
Carol Pollock 6,7
Arun V. Krishnan 8
Rajiv Agarwal 9
George Bakris 10
David M. Charytan 11
Dick de Zeeuw 12
Hiddo J.L. Heerspink 1,12
Adeera Levin 13
Bruce Neal 1,14,15
David C. Wheeler 1,16
Hong Zheng 18
Bernard Zinman 19
Kenneth W. Mahaffey 20
Vlado Perkovic 1,7
Meg J. Jardine 1,21,22
Brendan Smyth 1,22,23
and
CREDENCE Trial Investigators
Affiliations
1. The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia
2. Department of Nephrology, Peking University Shenzhen Hospital, Shenzhen, China
3. Department of Renal Medicine, Prince of Wales Hospital, Sydney, New South Wales, Australia
4. Department of Neurosurgery, West China Hospital, Sichuan University, Chengdu, China
5. Department of Cardiology, Royal Prince Alfred Hospital, Sydney Medical School, Sydney, New South Wales, Australia
6. Kolling Institute of Medical Research, Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia
7. Royal North Shore Hospital, Sydney, New South Wales, Australia
8. Prince of Wales Clinical School, University of New South Wales, Australia
9. Indiana University School of Medicine and VA Medical Center, Indianapolis, IN, USA
10. Department of Medicine, University of Chicago Medicine, Chicago, IL, USA
11. Nephrology Division, New York University Langone Medical Center, New York University School of Medicine, New York, NY, USA
12. Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
13. Division of Nephrology, University of British Columbia, Vancouver, British Columbia, Canada
14. The Charles Perkins Centre, University of Sydney, Sydney, New South Wales, Australia
15. Imperial College London, London, United Kingdom
16. Department of Renal Medicine, University College London Medical School, London, United Kingdom
17. Renal Division of Peking University First Hospital, Beijing, China
18. Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, Canada
19. Department of Medicine, Stanford Center for Clinical Research, Stanford University School of Medicine, Stanford, CA, USA
20. Concord Repatriation General Hospital, Sydney, New South Wales, Australia
21. NHMRC Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia
22. Department of Renal Medicine, St George Hospital, Sydney, New South Wales, Australia

Deleted: <df>The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia</df>
The impact of canagliflozin on the risk of neuropathy events: results from the CREDENCE trial

Background
Sodium-glucose cotransporter 2 inhibitors reduce the risk, and progression, of diabetic kidney disease. We hypothesized that sodium-glucose cotransporter 2 inhibitors could similarly improve the microvascular complication of neuropathy.

Methods
The CREDENCE trial randomized participants with type 2 diabetes and albuminuria to canagliflozin or placebo. Neuropathy events were defined as any reported adverse event with a Medical Dictionary for Regulatory Activities (MedDRA) term consistent with peripheral or autonomic neuropathy. The effect of canagliflozin on neuropathy events was calculated by Cox regression. In secondary analyses the endpoint was restricted to sensorimotor polyneuropathy, diabetic neuropathy, or non-autonomic neuropathy events, and subgroups were analysed. P-values adjusted for multiplicity using the Holm-Bonferroni correction were derived for the subgroup analyses.

Results
Half (48.8%) of the 4401 participants had a diagnosis of neuropathy at baseline. Over a median of 2.45 years follow up, 657 people experienced a first neuropathy event (63.2 per 1000 patient-years). The incidence of neuropathy events was similar in people randomized to canagliflozin and placebo.
(334/2202 vs. 323/2199; HR 1.04, 95% CI 0.89 to 1.21, p=0.66). Canagliflozin had no impact on sensorimotor polyneuropathy (HR 0.93, 95% CI 0.69 to 1.25, p=0.63), diabetic neuropathy (HR 0.91, 95% CI 0.68 to 1.22, p=0.52), or non-autonomic neuropathy (HR 1.03, 95% CI 0.87 to 1.21, p=0.77). The lack of effect on neuropathy events was consistent in subgroup analyses.

**Conclusions**

Canagliflozin did not affect the risk of neuropathy events in the CREDAENCE trial despite clear benefits for nephropathy, cardiovascular disease and glycaemic control.